LIGAND PHARMACEUTICALS INC 8-K

What Happened

• Ligand Pharmaceuticals Inc. announced on June 25, 2026 that it closed a private placement of $700.0 million aggregate principal amount of 0.00% Convertible Senior Notes due September 15, 2031 (the “Notes”), including the full exercise of an initial purchaser option for an additional $75.0 million. The Notes were issued under an indenture with U.S. Bank Trust Company, N.A. as trustee. The Notes pay no regular interest, may pay special interest in limited circumstances, and are convertible under specified conditions (and freely convertible on/after June 15, 2031 until shortly before maturity).

Key Details

• Offering size and proceeds: $700.0M principal; net proceeds ≈ $678.2M after fees and expenses.
• Use of proceeds: ≈ $72.9M used to pay for convertible note hedge transactions; ≈ $60.0M (plus cash on hand) used to repurchase 228,859 shares at $262.17 per share from certain purchasers.
• Conversion terms: initial conversion rate 2.9916 shares per $1,000 principal (≈ $334.27 per share), ~27.5% premium to the June 22, 2026 Nasdaq close. Conversion mechanics allow cash and/or stock settlement at the company’s election.
• Hedging and warrants: Company entered Purchased Options covering ~2.09M shares at $334.2693 strike to limit dilution and sold Warrants covering up to the same number of shares at a $524.34 strike (warrants could be dilutive if in-the-money).
• Redemption/repurchase mechanics: Company may not redeem before Sept 21, 2029; may redeem after that subject to stock-price tests (130% trigger) and minimum outstanding amount rules. Holders may require repurchase on certain “fundamental change” events at 100% of principal plus accrued special interest.

Why It Matters

• The transaction raises substantial capital (~$678M net) without regular cash interest payments, which can support operations or strategic needs while delaying cash interest burden. However, the convertible feature and related warrant transactions introduce potential future dilution to common shareholders depending on stock performance and conversions. The company also used part of the proceeds to buy back shares from note purchasers and to pay for hedging arrangements that are intended to mitigate dilution upon conversion. Investors should note the conversion price, timing windows for conversion/redemption, and the presence of warrants and hedges when assessing dilution risk and capital structure changes.